Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Saccharomyces boulardii CNCM I-745
- Development stage
- Unknown
- Lead developer
- Ann & Robert H Lurie Children's Hospital of Chicago
- Modality
- Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**Saccharomyces boulardii CNCM I-745** is a live, nonpathogenic probiotic yeast strain marketed in the United States as Florastor. In the Lurie Children's Hospital-sponsored study NCT06149676, Florastor 250 mg is being evaluated as daily prophylaxis alongside ciprofloxacin treatment at the first subsequent susceptible urinary tract infection in children with recurrent urinary tract infection. The probiotic is intended to modulate intestinal microbiota and mucosal immune function rather than directly kill urinary pathogens; its efficacy for preventing recurrent urinary tract infection remains investigational. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06149676))
- Brand names
- Florastor
- Other names
- S. boulardiiSaccharomyces boulardiiSaccharomyces boulardii lyo CNCM I-745
02
Targets
DNA gyraseTopo IV (Bacterial Topoisomerase IV)
Beyond the preview
Go deeper on Saccharomyces boulardii CNCM I-745.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Saccharomyces boulardii CNCM I-745.